A Study of TRK-950 in Patients With Advanced Solid Tumors
A phase 1/2 trial of TRK-950, Nivolumab in melanoma, run by Toray Industries, Inc, now recruiting.
Overview
A Study of TRK-950 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05423262 by Toray Industries, Inc, with 49 participants planned, started 2022-07-06 and due to reach its primary completion in 2027-12. Interventions recorded: TRK-950, TRK-950, TRK-950, Nivolumab, TRK-950. Conditions listed: Solid Tumor, Melanoma. No results are recorded here; the registry entry is the source.
Setting
A Phase I/II Study of TRK-950 in Patients With Advanced Solid Tumors
Phase
Phase 1/2
Sponsor
Toray Industries, Inc
Registry
Enrolled
49
Similar pages
not linked directly; found by shared links- TrialEffectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
- TrialA Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
- TrialMC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- TrialClinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
- TrialStudy Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
- TrialA Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
- TrialA Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed
- TrialStudy to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma